Abstract:<span class="a-plus-plus abstract-section id-a-sec1"><h3 class="a-plus-plus">Introduction</h3><p class="a-plus-plus">Traditional statistical techniques for extrapolating short-term survival data for anticancer therapies assume the same mortality rate for noncured and "cured" patients, which is appropriate for projecting survival of non-curative therapies but may lead to an underestimation of the treatment effectiveness for potentially curative therapies. Our objective was to ascertain research trends in survival extrapolation techniques used to project the survival benefits of chimeric antigen receptor T cell (CAR-T) therapies.</p></span><span class="a-plus-plus abstract-section id-a-sec2"><h3 class="a-plus-plus">Methods</h3><p class="a-plus-plus">A global systematic literature search produced a review of survival analyses of CAR-T therapies, published between January 1, 2015 and December 14, 2020, based on publications sourced from MEDLINE, scientific conferences, and health technology assessment agencies. Trends in survival extrapolation techniques used, and the rationale for selecting advanced techniques, are discussed.</p></span><span class="a-plus-plus abstract-section id-a-sec3"><h3 class="a-plus-plus">Results</h3><p class="a-plus-plus">Twenty publications were included, the majority of which (65%, <em class="a-plus-plus">N</em> = 13) accounted for curative intent of CAR-T therapies through the use of advanced extrapolation techniques, i.e., mixture cure models [MCMs] (<em class="a-plus-plus">N</em> = 10) or spline-based models (<em class="a-plus-plus">N</em> = 3). The authors' rationale for using the MCM approach included (a) better statistical fits to the observed Kaplan–Meier curves (KMs) and (b) visual inspection of the KMs indicated that a proportion of patients experienced long-term remission and survival which is not inherently captured in standard parametric distributions.</p></span><span class="a-plus-plus abstract-section id-a-sec4"><h3 class="a-plus-plus">Discussion</h3><p class="a-plus-plus">Our findings suggest that an advanced extrapolation technique should be considered in base case survival analyses of CAR-T therapies when extrapolating short-term survival data to long-term horizons extending beyond the clinical trial duration.</p></span><span class="a-plus-plus abstract-section id-a-sec5"><h3 class="a-plus-plus">Conclusion</h3><p class="a-plus-plus">Advanced extrapolation techniques allow researchers to account for the proportion of patients with an observed plateau in survival from clinical trial data; by only using standard-partitioned modeling, researchers may risk underestimating the survival benefits for the subset of patients with long-term remission. Sensitivity analysis with an alternative advanced extrapolation technique should be implemented and re-assessment using clinical trial extension data and/or real-world data should be conducted as longer-term data become available.</p></span>

Statistical considerations in long-term efficacy evaluation of anti-cancer therapies

Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the <scp>IMpower131</scp> Study

Statistical Considerations for Evaluating Treatment Effect under Various Non-proportional Hazard Scenarios

Improving Collection and Analysis of Overall Survival Data

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Modeling Long-term Outcomes and Treatment Effects After Androgen Deprivation Therapy for Prostate Cancer

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Estimand-based Inference in Presence of Long-Term Survivors

Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trial in Health Technology Assessment

Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis

Landmark mediation survival analysis using longitudinal surrogate

Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer

Analysis of survival data with non-proportional hazards: A comparison of propensity score weighted methods

A simulation study of methods for handling disease progression in dose-finding clinical trials

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship

Optimality of testing procedures for survival data

Time-to-event estimands and loss to follow-up in oncology in light of the estimands framework

Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis

Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials

Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review